What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Cladribine shows comparable efficacy to existing treatments for relapsing-remitting multiple sclerosis, as it reduces relapses and delays disability progression compared to placebo. However, the evidence does not demonstrate a clear superiority over other treatments like alemtuzumab and fingolimod, leading to a rating of B++.
Does the economic case hold at the expected price? — Cost effectiveness
Cladribine is considered cost-effective compared to other treatments, with the committee concluding that it dominates all other treatments in terms of cost-effectiveness, thus justifying an A+ rating.
Is there quality-of-life evidence payers weigh? — Quality of life
The guidance indicates that cladribine is less disruptive to daily routines compared to existing treatments, which require more frequent administration. This suggests a moderate improvement in quality of life, justifying an A rating.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile of cladribine is favorable, with manageable adverse events reported. The committee noted that the treatment requires less frequent monitoring, which supports a very good safety rating.
Was the drug compared against what payers expect? — Comparator Selection
The committee concluded that the comparators used in the appraisal (alemtuzumab and fingolimod) are appropriate for the patient population, leading to a good rating for comparator selection.
Is the population defined the way payers need it? — Patient Population and Subgroups
The subgroups defined for the appraisal are considered broadly representative of the intended patient population, with appropriate definitions for rapidly evolving severe and suboptimally treated relapsing-remitting multiple sclerosis.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Cladribine can be integrated into existing care pathways with minor adjustments, as it requires less frequent dosing and monitoring compared to other treatments.
Are the wider system costs understood? — Resource Use and Cost Implications
The economic analysis indicates that cladribine is less costly than other treatments and requires less frequent dosing, suggesting a favorable budget impact.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base includes a large RCT (CLARITY trial) with a robust design, although some concerns about the small size of post-hoc subgroups exist. Overall, the evidence is considered acceptable.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are uncertainties regarding the effectiveness of cladribine compared to its comparators, particularly in the smaller subgroups. This leads to a moderate rating for uncertainty.
